Rebecca C. Arend, MD

Articles

The Future Management of Cervical Cancer: Novel Agents and Clinical Pearls for Community Onclogists

November 1st 2021

Rounding out her discussion on the use of tisotumab vedotin in cervical cancer, Rebecca Arend, MD, MPH, considers other agents being investigated and how that may impact the future treatment landscape.

FDA Approval of Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

November 1st 2021

A brief review of the FDA approval and implications of tisotumab vedotin in patients with recurrent or metastatic cervical cancer.

Interim Results of the InnovaTV 205 Trial in Cervical Cancer

November 1st 2021

Considerations for the interim results of innovaTV 205, which tested tisotumab vedotin alone or in combination with other agents for patients with cervical cancer.

InnovaTV 204 Trial in Cervical Cancer: Study Design and Key Efficacy Results

November 1st 2021

Rebecca Arend, MD, MPH, reviews the study design and results from innovaTV 204, which tested tisotumab vedotin in previously treated, recurrent, or metastatic cervical cancer.

Evolving Therapy in Cervical Cancer: Tisotumab Vedotin’s Mechanism of Action

November 1st 2021

A historical perspective on the management of recurrent or metastatic cervical cancer, followed by expert insight on tisotumab vedotin’s mechanism of action.

Dr. Arend on Unmet Needs in Platinum-Resistant Ovarian Cancer

July 22nd 2020

Rebecca C. Arend, MD, discusses the unmet needs in of patients with platinum-resistant ovarian cancer.

Dr. Arend on FDA Approval of Frontline Bevacizumab in Ovarian Cancer

June 13th 2018

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the FDA approval of bevacizumab (Avastin) as a frontline treatment in combination with carboplatin and paclitaxel, followed by bevacizumab alone, for women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Dr. Arend on Novel Combination Strategies in Gynecologic Cancer

February 17th 2018

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses novel combination strategies in gynecologic cancer.

Dr. Arend on the Rationale of Novel Combinations in Gynecologic Cancer

February 10th 2018

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the rationale behind novel combination strategies for patients with gynecologic cancer.

Dr. Arend Discusses Biomarkers in Endometrial Cancer

August 11th 2017

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses biomarkers in endometrial cancer.

Dr. Arend Discusses MSI Testing in Gynecologic Malignancies

August 10th 2017

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses microsatellite instability testing in patients with gynecologic malignancies.

Dr. Arend on the PORTEC-3 Trial for Endometrial Cancer

July 7th 2017

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the PORTEC-3 trial for patients with endometrial cancer.

Dr. Arend on Personalized Medicine for Endometrial Cancer

June 9th 2017

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses personalized medicine for patients with endometrial cancer.